New treatment options for chronic constipation: Mechanisms, efficacy and safety

Canadian Journal of Gastroenterology

Volumn 25, Issue SUPPL.B, 2011, Pages

  Michael, Camilleri ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Opiate; Prokinetics; Secretagogues

Indexed keywords

17 METHYLNALTREXONE; A 3309; ALVIMOPAN; BILE ACID; CHENODEOXYCHOLIC ACID; CHLORIDE ION; CISAPRIDE; CODEINE; GUANYLATE CYCLASE; GUANYLATE CYCLASE C RECEPTOR; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; NARONAPRIDE; NKTR 118; OPIATE; OSMOTIC AGENT; OXYCODONE; PLACEBO; PLECANATIDE; PRUCALOPRIDE; SEROTONIN 4 AGONIST; TAPENTADOL; TD 1211; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

BILE ACID METABOLISM; CHRONIC DISEASE; CHRONIC OSTEOARTHRITIS RELATED KNEE PAIN; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IRRITABLE COLON; ISCHEMIC HEART DISEASE; KNEE PAIN; LOW BACK PAIN; NAUSEA; NONHUMAN; OPIATE INDUCED CONSTIPATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84869837226     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Voderholzer WA, Schatke W, Mühldorfer BE, Klauser AG, Birkner B, Müller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997;92:95-8.
2. Suares NC, Ford AC. Systematic review: The effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011;33:895-901.
3. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007;102:1436-41.
4. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Efficacy and safety of bisacodyl in the acute treatment of constipation: A double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2006;23:1479-88.
5. Kim DY, Camilleri M. Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709.
6. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71:533-54.
7. Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006;24:59-69.
8. Maddern GJ, Jamieson GG, Myers JC, Collins PJ. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 1991;32:470-4.
9. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998;12:761-6.
10. Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. FASEB J 1996;10:1398-407.
11. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde GM. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
12. Quigley EM, Wald A, Fidelholtz J, et al. Safety and tolerability of tegaserod in patients with chronic constipation: Pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006;4:605-13.
13. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst 2007;(4):CD003960.
14. Demaeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: Similar but not the same. Neurogastroenterol Motil 2008;20:99-112.
15. Mohamand S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-8.
16. Nilsson T, Longmore J, Shaw D, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49-56.
17. MaassenVanDenBrink, Reekers M, Bax WA, Saxena PR. Human isolated coronary artery contraction to sumatriptan characterized by the selective 5-HT1B/1D receptor antagonist GR55562. Pharmacol Toxicol 2000;86:287-90.
18. Villalón CM, Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: A pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedeberg's Arch 2007;376:45-63.
19. United States Food and Drug Administration. 〈www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284. htm〉 (Accessed on June 27, 2011).
20. Beattie DT, Smith JA, Marquess D, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004;143:549-60.
21. Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: Getting the balance right. Gut 2010;59:1288-96.
22. De Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: An operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther 2006;317:955-64.
23. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60.
24. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67.
25. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54.
26. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28.
27. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65.
28. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: A double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-63.
29. Smith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, Humphrey PP. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:125-37.
30. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:139-47.
31. Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-9.
32. Goldberg M, Li YP, Johanson JF, et al. Clinical trial: The efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010;32:1102-12.
33. Dennis D, Palme M, Irwin I, Druzgala P, Teichman S. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004;126:A641.
34. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-8.
35. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: Molecular basis and regulatory aspects. Annu Rev Physiol 2000;62:535-72.
36. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol 2004;287:C1173-83.
37. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009;137:976-85.
38. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-35.
39. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol 2006;290:G942-7.
40. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol 2009;296:G295-301.
41. Cuppoletti J, Malinowska DH, Chakrabarti J, Ueno R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat 2008;86:56-60.
42. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-61.
43. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7.
44. Vaandrager AB. Structure and function of the heat-stable enterotoxin receptor guanylyl cyclase C. Mol Cell Biochem 2002;230:73-83.
45. -secretion by uroguanylin. Am J Physiol 1998;274:G633-44.
46. Donowitz M, Cha B, Zachos NC, et al. NHERF family and NHE3 regulation. J Physiol 2005;567:3-11.
47. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8.
48. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35.
49. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32.
50. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95.
51. Shailubhai K, Gerson WA, Talluto C, Jacob GS. SP-304 to treat GI disorders - effects of a single, oral-dose of SP-304 on safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Gastroenterology 2009;136(Suppl 1):A641. (Abst)
52. Shailubhai K, Talluto C, Comiskey S, Foss JA, Joslyn A, Jacob G. Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation. Am J Gastroenterol 2010;105:S487-8.
53. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-58.
54. Chadwick VS, Gaginella TS, Carlson GL, Debongnie JC, Phillips SF, Hofmann AF. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979;94:661-74.
55. Conley DR, Coyne MJ, Bonorris GG, Chung A, Schoenfield LJ. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis 1976;21:453-8.
56. Mekhjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: Perfusion studies in man. J Clin Invest 1971;50:1569-77.
57. Wingate DL, Phillips SF, Hofmann AF. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J Clin Invest 1973;52:1230-6.
58. Kirwan WO, Smith AN, Mitchell WD, Falconer JD, Eastwood MA. Bile acids and colonic motility in the rabbit and the human. Gut 1975;16:894-902.
59. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002;282:G443-9.
60. Odunsi ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-65.
61. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: A pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010;139:1549-58.
62. Bazzoli F, Malavolti M, Petronelli A, Barbara L, Roda E. Treatment of constipation with chenodeoxycholic acid. J Int Med Res 1983;11:120-3.
63. Gillberg, PG, Dahlström M, Starke I, et al. The IBAT inhibition by A3309 - a potential mechanism for the treatment of constipation. Gastroenterology 2010;5(Suppl 1):224.
64. Simren M, Abrahamsson H, Bajor A, et al. The IBAT inhibitor A3309 - a promising treatment option for patients with chronic idiopathic constipation. Gastroenterology 2010;5(Suppl 1):223.
65. Wong B, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in functional constipation. Gastroenterology 2011;140(Suppl 1):S146-7 .
66. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transport inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011 May 24 (E-pub ahead of print).
67. Morvay K, Szentleleki K, Torok G, Pinter A, Borzsonyi M, Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats. Dis Colon Rectum 1989;32:860-3.
68. Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year post trial follow-up report from the POSCH: Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998;158:1253-61.
69. Buchwald H, Rudser KD, Williams SE, Michalek VN, Vagasky J, Connett JE. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010;251:1034-40.
70. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: Short and long term effects in the intestine. Scand J Gastroenterol 2010;45:645-64.
71. Camilleri M. Opioid-induced constipation: Challenges and therapeutic opportunities. Am J Gastroenterol 2011 Feb 22 (Epub ahead of print).
72. Basilisco G, Camboni G, Bozzani A, et al. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci 1987;32:829-32.
73. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988;94:1351-6.
74. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9.
75. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54.
76. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64.
77. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74.
78. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:984-93.
79. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000;283:367-72.
80. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997;61:467-75.
81. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469-75.
82. Yuan CS, Foss JF, O'Connor M, et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: A pilot study. Pain 1999;83:631-5.
83. Yuan CS, Foss JF, O'Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000;67:398-404.
84. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43.
85. Wong BS, Rao AS, Camilleri M, et al. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther 2010;32:884-93.
86. Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40:734-46.
87. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-40.
88. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study. Clin Gastroenterol Hepatol 2005;3:784-91.
89. Neumann TA, van Paaschen H, Marcantonio A, et al. Clinical investigation of oral NKTR-118 as a selective oral peripheral opioid antagonist (Abst 27). Proceedings of the 18th Annual Clinical Meeting of the American Academy of Pain Management. Las Vegas, September 27 to 30, 2007.
90. Webster L, et al. Efficacy, safety and pharmacokinetices of oral NKTR-118 in patients with opiod-induced constipation: Results of a randomized, double-blind, placebo-controlled phase 2 study. Am J Gastroenterol 2009;104:S174.
91. Theravance. 〈http://files.shareholder.com/downloads/THERA/ 1065777793x0x411486/56fc683c-c436-4a24-85de-08622a292435/THRX-1021.pdf〉 (Accessed on June 27, 2011).
92. Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131-9.
93. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: Results of a randomized, double-blind, placebo- and active-controlled phase 3 study. Clin Drug Invest 2010;30:489-505.
94. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-804.
95. Slappendel R, Simpson K, Dubois D, et al. Development of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-17.
96. Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912-21.